SCHEMBL6790633

SCHEMBL6790633

O=C1OC(c2ccccc2C(=O)O)=NC1=Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MASP2 O00187 1/20 0.48
CSNK2A2 P19784 4/20 0.48
CSNK2B P67870 4/20 0.48
CSNK2A1 P68400 4/20 0.48
DAPK3 O43293 1/20 0.47
ALOX5 P09917 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NOTUM Q6P988 6/20 0.43
F2 P00734 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
F10 P00742 1/20 0.42
PLG P00747 1/20 0.42
PLAU P00749 1/20 0.42
PLAT P00750 1/20 0.42
KLKB1 P03952 1/20 0.42
POLB P06746 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
PLCG2 P16885 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6790629 1.00 MASP2 (0.48) MASP2CSNK2A2CSNK2BCSNK2A1DAPK3
SCHEMBL6795306 0.81 PLCG2 (0.60) MASP2CSNK2A2CSNK2BCSNK2A1DAPK3
SCHEMBL6795309 0.81 PLCG2 (0.60) MASP2CSNK2A2CSNK2BCSNK2A1DAPK3
SCHEMBL6795962 0.80 CSNK2A2 (0.51) CSNK2A2CSNK2BCSNK2A1DAPK3ALOX5
SCHEMBL6795960 0.80 CSNK2A2 (0.51) CSNK2A2CSNK2BCSNK2A1DAPK3ALOX5
SCHEMBL6794321 0.80 CSNK2A2 (0.72) CSNK2A2CSNK2BCSNK2A1DAPK3ALOX5
SCHEMBL6794318 0.80 CSNK2A2 (0.72) CSNK2A2CSNK2BCSNK2A1DAPK3ALOX5
SCHEMBL6792570 0.78 CSNK2A2 (0.59) CSNK2A2CSNK2BCSNK2A1DAPK3ALOX5
SCHEMBL6792564 0.78 CSNK2A2 (0.59) CSNK2A2CSNK2BCSNK2A1DAPK3ALOX5
SCHEMBL13236198 0.78 NOTUM (0.65) MASP2DAPK3ALOX5NOTUMF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis APP, PSEN1, PSEN2 MASP2 1759/4885CSNK2A2 1982/4885CSNK2B 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.